- Home
- BRZE vs RARE Comparison
BRZE vs RARE Comparison
Compare BRZE & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRZE
- RARE
- Stock Information
- Founded
- BRZE 2011
- RARE 2010
- Country
- BRZE United States
- RARE United States
- Employees
- BRZE N/A
- RARE N/A
- Industry
- BRZE Computer Software: Prepackaged Software
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- BRZE Technology
- RARE Health Care
- Exchange
- BRZE Nasdaq
- RARE Nasdaq
- Market Cap
- BRZE 3.8B
- RARE 3.6B
- IPO Year
- BRZE 2021
- RARE 2014
- Fundamental
- Price
- BRZE $37.51
- RARE $37.82
- Analyst Decision
- BRZE Strong Buy
- RARE Strong Buy
- Analyst Count
- BRZE 21
- RARE 15
- Target Price
- BRZE $53.57
- RARE $95.93
- AVG Volume (30 Days)
- BRZE 1.6M
- RARE 736.1K
- Earning Date
- BRZE 03-27-2025
- RARE 05-01-2025
- Dividend Yield
- BRZE N/A
- RARE N/A
- EPS Growth
- BRZE N/A
- RARE N/A
- EPS
- BRZE N/A
- RARE N/A
- Revenue
- BRZE $593,410,000.00
- RARE $560,230,000.00
- Revenue This Year
- BRZE $18.34
- RARE $19.15
- Revenue Next Year
- BRZE $17.29
- RARE $32.11
- P/E Ratio
- BRZE N/A
- RARE N/A
- Revenue Growth
- BRZE 25.78
- RARE 29.01
- 52 Week Low
- BRZE $29.18
- RARE $36.71
- 52 Week High
- BRZE $48.33
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- BRZE 50.76
- RARE 39.28
- Support Level
- BRZE $35.89
- RARE $36.71
- Resistance Level
- BRZE $39.44
- RARE $39.21
- Average True Range (ATR)
- BRZE 2.03
- RARE 1.32
- MACD
- BRZE 0.52
- RARE 0.01
- Stochastic Oscillator
- BRZE 44.81
- RARE 29.02
About BRZE Braze Inc.
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries. The company offers a single, vertically integrated platform that encompasses the various functionalities, or layers, required for modern customer engagement: data ingestion, classification, orchestration, personalization, and action, all of which is supported by Sage AI by Braze, its AI engine designed to power AI functionality across all layers of this stack. It generates a majority of its revenue from the United States.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.